Endothelin-1 (ET-1) Levels as Predictors of Pulmonary Hypertension Risk in Premature Infants with Bronchopulmonary Dysplasia (BPD)

Study Type/Phase: Observational

A lung condition called bronchopulmonary dysplasia (BPD) is a major cause of poor outcomes and death for premature infants. Infants with BPD are also at high risk for pulmonary hypertension (PH)—an important contributor to their condition. Previous research has suggested that a protein in the blood, endothelin-1 (ET-1), is associated with pulmonary disease. This study aims to investigate the incidence of pulmonary hypertension and levels of ET-1 among premature babies with and without BPD, helping define the high-risk population within the study hospitals. This study will also enroll control subjects, which would be term infants (greater than or equal to 37 weeks gestational age) who do not have respiratory issues.

Speak with your doctor to determine whether you meet the following criteria for participation in this study.

Inclusion Criteria Exclusion Criteria
  • Premature infants (<30 weeks EGA)
  • Major congenital malformations (cardiac, respiratory, gastrointestinal)
  • congenital infection, and/or
  • known genetic syndromes (i.e. trisomy 21)

Principal Investigator

Christine Johnson, MD

Sponsor

Stanford University

NCT Number

NCT01516398

Contact

Christine Johnson, MD
clcjohns@stanford.edu

For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.

Share this page: